SELLAS Life Sciences (SLS) Equity Average (2011 - 2026)
SELLAS Life Sciences (SLS) reported Equity Average of $89.1 million for Q1 2026, up 378.95% year-over-year from $18.6 million in Q1 2025, and up 53.03% on a QoQ basis from $58.3 million in Q4 2025.
SELLAS Life Sciences (SLS) has 16 years of Equity Average data on file, last reported at $89.1 million in Q1 2026.
- Quarterly Equity Average rose 378.95% year-over-year to $89.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.1 million (up 378.95% YoY) and the FY2025 annual result came in at $40.2 million, up 5295.3% from the prior year.
- Equity Average rose to $89.1 million in Q1 2026 per SLS's latest filing, from $58.3 million in the prior quarter.
- Across five years, Equity Average topped out at $89.1 million in Q1 2026 and bottomed at -$5.9 million in Q4 2023.
- The 5-year median for Equity Average is $11.5 million (2022), against an average of $18.8 million.
- The widest annual swing landed in 2023, when Equity Average plunged 167.65%; it then surged 2079.39% in 2025.
- Tracing SLS's Equity Average over 5 years: stood at $8.7 million in 2022, then sank by 167.65% to -$5.9 million in 2023, then jumped by 314.84% to $12.7 million in 2024, then soared by 359.44% to $58.3 million in 2025, then jumped by 53.03% to $89.1 million in 2026.
- Per Business Quant, the three latest SLS Equity Average figures stand at $89.1 million (Q1 2026), $58.3 million (Q4 2025), and $35.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 89.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.14 Mn |
| Dec 31, 2025 | 58.25 Mn |
| Sep 30, 2025 | 35.89 Mn |
| Jun 30, 2025 | 26.95 Mn |
| Mar 31, 2025 | 18.61 Mn |
| Dec 31, 2024 | 12.68 Mn |
| Sep 30, 2024 | 9.40 Mn |
| Jun 30, 2024 | 6.30 Mn |
| Mar 31, 2024 | 854,000.00 |
| Dec 31, 2023 | -5.90 Mn |
| Sep 30, 2023 | 508,000.00 |
| Jun 30, 2023 | 9.01 Mn |
| Mar 31, 2023 | 9.01 Mn |
| Dec 31, 2022 | 8.72 Mn |
| Sep 30, 2022 | 15.83 Mn |
| Jun 30, 2022 | 11.54 Mn |
| Mar 31, 2022 | 12.19 Mn |
| Dec 31, 2021 | 23.48 Mn |
| Sep 30, 2021 | 30.01 Mn |
| Jun 30, 2021 | 31.08 Mn |
| Mar 31, 2021 | 28.35 Mn |
| Dec 31, 2020 | 17.95 Mn |
| Sep 30, 2020 | 5.87 Mn |
| Jun 30, 2020 | 5.92 Mn |
| Mar 31, 2020 | 7.08 Mn |
| Dec 31, 2019 | 8.37 Mn |
| Sep 30, 2019 | 12.49 Mn |
| Jun 30, 2019 | 8.64 Mn |
| Mar 31, 2019 | 4.10 Mn |
| Dec 31, 2018 | 11.85 Mn |
| Sep 30, 2018 | 7.99 Mn |
| Jun 30, 2018 | -1.90 Mn |
| Mar 31, 2018 | 376,000.00 |
| Dec 31, 2017 | 8.35 Mn |
| Sep 30, 2017 | 16.88 Mn |
| Jun 30, 2017 | 23.16 Mn |
| Mar 31, 2017 | 11.10 Mn |
| Dec 31, 2016 | 9.47 Mn |
| Sep 30, 2016 | 22.13 Mn |
| Jun 30, 2016 | 16.37 Mn |
| Mar 31, 2016 | 75,500.00 |
| Dec 31, 2015 | 10.08 Mn |
| Sep 30, 2015 | 40.89 Mn |
| Jun 30, 2015 | 54.22 Mn |
| Mar 31, 2015 | 48.07 Mn |
| Dec 31, 2014 | 33.96 Mn |
| Sep 30, 2014 | 29.59 Mn |
| Jun 30, 2014 | 37.41 Mn |
| Mar 31, 2014 | 26.20 Mn |
| Dec 31, 2013 | 20.25 Mn |
| Sep 30, 2013 | 24.93 Mn |
| Jun 30, 2013 | 19.27 Mn |
| Mar 31, 2013 | 25.53 Mn |
| Dec 31, 2012 | 20.96 Mn |
| Mar 31, 2012 | -229,000.00 |
| Dec 31, 2011 | 7.41 Mn |
| Sep 30, 2011 | 5.92 Mn |